BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE February 3, 2009, at 2 p.m.
Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
Biotie Therapies Corp. ("Company") has gained knowledge of the notifications regarding the following changes in holdings in accordance with Chapter 2, Section 9 of the Finnish Securities Markets Act.
Pequot Healthcare Fund, L.P., Pequot Healthcare Offshore Fund, Inc., Premium Series PCC Limited - Cell 32, Pequot Diversified Master Fund, Ltd., Pequot Healthcare Institutional Fund, L.P. and Pequot Healthcare Emerging Markets Master Fund, Ltd. have notified that as a result of share transactions carried out on 30 January, 2009, the aggregate holdings of these shareholders have decreased from above 15 % to 13.66 %.
Moreover, as a result of these share transactions carried out on 30 January 2009, the holdings of Pequot Healthcare Fund, L.P. have decreased from above 5 % to 4.69 %.
The changes in holdings in accordance with Chapter 2, Section 9 of the Finnish Securities Markets Act of which the Company has gained knowledge are described below.
|
Name of the shareholder |
Shares
prior to the transactions |
Shares
after the transactions
|
% of shares after the transactions
|
|
Pequot Healthcare Fund, L.P.
|
7,244,966
|
6,767,801
|
4.69
|
|
Pequot Healthcare Offshore Fund, Inc.
|
6,387,783
|
5,321,783
|
3.69
|
|
Premium Series PCC
Limited - Cell 32
|
2,111,387
|
1,741,590
|
1.21
|
|
Pequot Diversified Master Fund, Ltd.
|
1,314,100
|
1,084,000
|
0.75
|
|
Pequot Healthcare Institutional Fund, L.P.
|
2,254,305
|
1,859,906
|
1.29
|
|
Healthcare Emerging
Markets Fund, Ltd.
|
3,571,637
|
2,946,170
|
2.04
|
|
SUBTOTAL |
22,884,178
|
19,721,250
|
13.66
|
|
|
|
|
|
The registered number of shares in Biotie Therapies Corp. is 144 320 560 and the number of voting rights attached to the shares amounts to 144 320 560.
Turku, February 3, 2009
Timo Veromaa
President and CEO
For further information, please contact:
Timo Veromaa, President and CEO, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: timo.veromaa@biotie.com
www.biotie.com
DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media